A review of cancer immunotherapy: from the past, to the present, to the future Page 1 S87
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …

The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …

Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …

Immune checkpoint inhibitors (ICIs) are widely used for various malignancies. However,
their safety and efficacy in patients with a kidney transplant have not been defined. To …

Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …

Regulatory T (Treg) cells constitute a dynamic population that is essential for controlling
immune responses in health and disease. Defects in Treg cell function and decreases in …

Solid organ transplant (SOT) is frequently complicated by cancers, which render
immunosuppression challenging. Immune checkpoint inhibitors have emerged as …

Chronic immunosuppression in solid organ transplant recipients (SOTRs) leads to an
increased risk of a wide variety of cancers. Immune checkpoint inhibitor (ICI) therapy is …

In order to update recommendations on treatment, supportive care, education, and follow-up
of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary …

Renal toxicities have been increasingly recognized as complications of the immune
checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk …